Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: KRAS Wild-type, EGFR Expressing Metastatic Colorectal Cancer Condition: KRAS mutation-negative (wild-type), epidermal growth factor receptor (EGFR)-expressing colorectal cancer (CRC) in combination with irinotecan, fluorouracil, leucovorin for first-line treatment or in combination with irinotecan in patients refractory to irinotecan-based chemotherapy or as a single agent in failed oxaliplatin- and irinotecan-based chemotherapy or in patients intolerant to irinotecan |
Dose: Intravenous infusion – 400 mg/m2 Frequency: once (initial dose) Duration: over 120 minutes Note: Subsequent doses are 250 mg/m2 once weekly. |
|
Indication: KRAS Wild-type, EGFR Expressing Metastatic Colorectal Cancer Condition: KRAS mutation-negative (wild-type), epidermal growth factor receptor (EGFR)-expressing colorectal cancer (CRC) in combination with irinotecan, fluorouracil, leucovorin for first-line treatment or in combination with irinotecan in patients refractory to irinotecan-based chemotherapy or as a single agent in failed oxaliplatin- and irinotecan-based chemotherapy or in patients intolerant to irinotecan |
Dose: Intravenous infusion – 250 mg/m2 Frequency: once weekly (subsequent doses) Duration: over 60 minutes until disease progression or unacceptable toxicity |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: Pediatric |
Dose: No approved pediatric dosage available Note: No approved pediatric dosage available |
Administration
- Given as IV infusion
- Initial dose over 2 hours
Side Effect
- Rash/desquamation (95%)
- Fatigue (91%)
- Nausea (64%)
- Other pain (59%)
- Dry skin (57%)
- Constipation (53%)
- Dyspnea (49%)
- Pruritus (47%)
- Sensory neuropathy (45%)
- Diarrhea (42%)
- Vomiting (40%)
- Headache (38%)
- Infections with neutropenia (38%)
- Other dermatology (35%)
- Stomatitis (32%)
- Fatigue (31%)
- Nail changes (31%)
- Insomnia (27%)
- Fever (25%)
- Other gastrointestinal (22%)
- Infusion reactions (18%)
- Confusion (18%)
- Other pain, Grade 3 or 4 (18%)
- Rigors or chills (16%)
- Dyspnea, Grade 3 or 4 (16%)
- Rash/desquamation, Grade 3 or 4 (16%)
- Anxiety (14%)
- Depression (14%)
- Dehydration (13%)
- Mouth dryness (12%)
- Other gastrointestinal, Grade 3 or 4 (12%)
- Infections with neutropenia, Grade 3 or 4 (11%)
- Taste disturbance (10%)
- Nausea (6%)
- Confusion, Grade 3 or 4 (6%)
- Vomiting, Grade 3 or 4 (5%)
- Bone pain (4%)
- Infusion reactions, Grade 3 or 4 (3%)
- Fever, Grade 3 or 4 (3%)
- Constipation, Grade 3 or 4 (3%)
- Arthralgia, Grade 3 or 4 (3%)
- Diarrhea, Grade 3 or 4 (2%)
- Pruritus, Grade 3 or 4 (2%)
- Headache, Grade 3 or 4 (2%)
- Rigors or chills, Grade 3 or 4 (1%)
- Stomatitis, Grade 3 or 4 (1%)
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
No interactions listed
|
-
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
No specific contraindications listed
|
Monitor for general reactions
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Store vials under refrigeration at 2° to 8° C. Do not freeze.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.